(1) Kang S, et al. Targeting Interleukin-6 Signaling in Clinic. Immunity. (2019) 16;50(4):1007-1023.
(2) Song Z, et al. Molecular cross-talk of IL-6 in tumors and new progress in combined therapy. Thorac Cancer. (2018);9(6):669-675.
(3) Galoczova M, et al. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. (2018)22;23:12.
(4) Johnson DE, et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. (2018);15(4):234-248.
(5) Yan Lin et al. Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer. Onco Targets Ther. (2020)21;13:13023-13032.
(6) Moshapa FT, et al. Therapeutic Targeting of the Proinflammatory IL-6-JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus. Cardiol Res Pract. (2019)2;2019:9846312.
(7) Liu Y, et al. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. (2021);54(2):e12974.
(8) Kasembeli MM, et al. Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment. Int J Mol Sci. (2018)5;19(8):2299.
(9) Mohrherr J, et al. STAT3: Versatile Functions in Non-Small Cell Lung Cancer. Cancers (Basel). (2020)29;12(5):1107.